Butterbur Ze339 for the treatment of intermittent allergic rhinitis: dose-dependent efficacy in a prospective, randomized, double-blind, placebo-controlled study
Schapowal A
Published in Archives of Otolaryngology - Head and Neck Surgery
Methodology
Prospective, randomized, double-blind, placebo-controlled dose-ranging trial of butterbur extract Ze 339 (one tablet three or four times daily) over two weeks in patients with intermittent allergic rhinitis, using symptom score diaries.
Key Findings
Butterbur extract Ze 339 improved nasal symptom scores in intermittent allergic rhinitis in a dose-dependent manner, with the higher dose outperforming placebo and tolerability comparable to placebo.
Conclusions
Butterbur Ze339 is an effective, well-tolerated treatment for intermittent allergic rhinitis.
Limitations
Short two-week duration, symptom-diary endpoints, no active antihistamine comparator in this trial, industry sponsorship, and no DOI indexed for the record.
Related Health Concerns
Study Details
Access Study
This information is for educational purposes only. Always consult a healthcare professional before starting any supplement regimen.